Columbia Wanger Asset Management is Buying Celldex Therapeutics Inc. (NASDAQ:CLDX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Celldex Therapeutics Inc. (NASDAQ:CLDX) reported that Columbia Wanger Asset Management Llc. has picked up 6,195,855 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Columbia Wanger Asset Management Llc. to a total of 6,195,855 representing a 5.1% stake in the company.
For those not familiar with the company, Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
A glance at Celldex Therapeutics Inc. (NASDAQ:CLDX)’s key stats reveals a current market capitalization of 416.17 million based on 122.28 million shares outstanding and a price at last close of $3.45 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-08-25, Ellberger picked up 5,000 at a purchase price of $14.00. This brings their total holding to 53,500 as of the date of the filing.
On the sell side, the most recent transaction saw Catlin unload 25,000 shares at a sale price of $18.00. This brings their total holding to 35,109.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Celldex Therapeutics Inc. (NASDAQ:CLDX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Natera Inc. (NASDAQ:NTRA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Natera Inc. (NASDAQ:NTRA) reported that Claremont Creek Ventures L P. has picked up 7,020,856 of common stock as of 2017-02-09.
The acquisition brings the aggregate amount owned by Claremont Creek Ventures L P. to a total of 7,020,856 representing a 13.4% stake in the company.
For those not familiar with the company, Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).
A glance at Natera Inc. (NASDAQ:NTRA)’s key stats reveals a current market capitalization of 490.34 million based on 52.38 million shares outstanding and a price at last close of $9.31 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-06-19, Steuart picked up 66,621 at a purchase price of $11.94. This brings their total holding to 83,752 as of the date of the filing.
On the sell side, the most recent transaction saw Rosenman unload 1,850 shares at a sale price of $8.95. This brings their total holding to 34,755.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Natera Inc. (NASDAQ:NTRA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Cesca Therapeutics Inc. (NASDAQ:KOOL) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Cesca Therapeutics Inc. (NASDAQ:KOOL) reported that Haefling Carl. has picked up 454,400 of common stock as of 2017-02-09.
The acquisition brings the aggregate amount owned by Haefling Carl. to a total of 454,400 representing a 4.6% stake in the company.
For those not familiar with the company, Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.
A glance at Cesca Therapeutics Inc. (NASDAQ:KOOL)’s key stats reveals a current market capitalization of 28.53 million based on 9.79 million shares outstanding and a price at last close of $2.93 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-26, Boyalife picked up 6,102,942 at a purchase price of $2.52. This brings their total holding to 6,838,237 as of the date of the filing.
On the sell side, the most recent transaction saw Harris unload 2,200 shares at a sale price of $0.60. This brings their total holding to 4,490,410.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Cesca Therapeutics Inc. (NASDAQ:KOOL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Sramowicz Steven is Buying Rennova Health Inc. (NASDAQ:RNVA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Rennova Health Inc. (NASDAQ:RNVA) reported that Sramowicz Steven has picked up 3,855,659 of common stock as of 2017-02-01.
The acquisition brings the aggregate amount owned by Sramowicz Steven to a total of 3,855,659 representing a 23.0% stake in the company.
For those not familiar with the company, Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.
A glance at Rennova Health Inc. (NASDAQ:RNVA)’s key stats reveals a current market capitalization of 4.86 million based on 84.01 million shares outstanding and a price at last close of $0.070 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-07-14, Diamantis picked up 333,333 at a purchase price of $0.44. This brings their total holding to 681,526 as of the date of the filing.
On the sell side, the most recent transaction saw Alcatel-Lucent unload 7,843 shares at a sale price of $4.60. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Rennova Health Inc. (NASDAQ:RNVA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Iridian Asset Management Picked Up Post Holdings Inc. (NYSE:POST) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Post Holdings Inc. (NYSE:POST) reported that Iridian Asset Management has picked up 3,822,599 of common stock as of 2017-02-02.
The acquisition brings the aggregate amount owned by Iridian Asset Management to a total of 3,822,599 representing a 5.9% stake in the company.
For those not familiar with the company, Post Holdings, Inc. is a consumer packaged goods holding company. The Company operates through four segments, namely, Post Consumer Brands, Michael Foods Group, Active Nutrition and Private Brands. The Company’s Post Consumer Brands segment includes the Post Foods branded ready-to-eat cereal operations and the business of MOM Brands. Its Michael Foods Group segment produces and distributes egg products, refrigerated potato products, cheese and other dairy case products, and pasta products. Its Private Brands segment manufactures and distributes organic and conventional private label peanut butter and other nut butters, baking nuts, raisins and other dried fruit, and trail mixes.
A glance at Post Holdings Inc. (NYSE:POST)’s key stats reveals a current market capitalization of 5.40 billion based on 64.63 million shares outstanding and a price at last close of $83.5 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-02-08, Stiritz picked up 20,000 at a purchase price of $63.87. This brings their total holding to 23,091 as of the date of the filing.
On the sell side, the most recent transaction saw Koulouris unload 21,942 shares at a sale price of $85.33. This brings their total holding to 28,334.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Post Holdings Inc. (NYSE:POST) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Jennison Associates Llc. Picked Up Genmark Diagnostics Inc. (NASDAQ:GNMK) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Genmark Diagnostics Inc. (NASDAQ:GNMK) reported that Jennison Associates Llc. has picked up 3,222,716 of common stock as of 2017-02-03.
The acquisition brings the aggregate amount owned by Jennison Associates Llc. to a total of 3,222,716 representing a 6.9% stake in the company.
For those not familiar with the company, GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment.
A glance at Genmark Diagnostics Inc. (NASDAQ:GNMK)’s key stats reveals a current market capitalization of 517.68 million based on 46.40 million shares outstanding and a price at last close of $11.42 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-22, Kagnoff picked up 2,000 at a purchase price of $11.80. This brings their total holding to 35,048 as of the date of the filing.
On the sell side, the most recent transaction saw Mendel unload 9,098 shares at a sale price of $12.47. This brings their total holding to 133,301.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Genmark Diagnostics Inc. (NASDAQ:GNMK) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Just Picked Up Teladoc Inc. (NYSE:TDOC) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Teladoc Inc. (NYSE:TDOC) reported that Chp Iii Lp has picked up 4,480,468 of common stock as of 2017-02-03.
The acquisition brings the aggregate amount owned by Chp Iii Lp to a total of 4,480,468 representing a 9.7% stake in the company.
For those not familiar with the company, Teladoc, Inc., together with its subsidiaries, is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company operates through health services segment. Its solution connects its Members, with its over 3,000 board-certified physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation. Its enterprise scale platform is offered for real-time sharing of clinical and non-clinical data in real time among the Teladoc constituents, which include Members, Providers, physician network operations center staff, nurses, SureScripts for electronic medication prescription writing, routing and fulfillment and health plans for claims processing, clinical summaries and clinical alerts.
A glance at Teladoc Inc. (NYSE:TDOC)’s key stats reveals a current market capitalization of 1.11 billion based on 52.85 million shares outstanding and a price at last close of $20.08 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-17, Outland picked up 10,000 at a purchase price of $10.70. This brings their total holding to 69,089 as of the date of the filing.
On the sell side, the most recent transaction saw Hirschhorn unload 900 shares at a sale price of $20.00. This brings their total holding to 239,987.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Teladoc Inc. (NYSE:TDOC). as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Perrigo Co Plc. (NYSE:PRGO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Perrigo Co Plc. (NYSE:PRGO) reported that Starboard Value LP. has picked up 9,641,425 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Starboard Value LP. to a total of 9,641,425 representing a 6.7% stake in the company.
For those not familiar with the company, Perrigo Company plc is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies.
A glance at Perrigo Co Plc. (NYSE:PRGO)’s key stats reveals a current market capitalization of 11.19 billion based on 143.37 million shares outstanding and a price at last close of $77.76 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-21, Parker picked up 2,500 at a purchase price of $88.75. This brings their total holding to 2,500 as of the date of the filing.
On the sell side, the most recent transaction saw Brown unload 2,097 shares at a sale price of $89.44. This brings their total holding to 10,007.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Perrigo Co Plc. (NYSE:PRGO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.